Management of HER2-Low Metastatic Breast Cancer: A Comprehensive Statement by an Expert Group from the Middle East and Africa Region

Approximately 50 to 67% of breast cancers (BCs), traditionally categorized as human epidermal growth factor receptor 2 (HER2)-negative, but demonstrating low HER2 expression, are now being defined as a new HER2-low subset or HER2-low category of BC. For metastatic BC (mBC), standard therapy options...

Full description

Bibliographic Details
Published in:	Middle East Journal of Cancer
Main Authors:	Shaheenah Dawood, Mohsen Mokhtar, Ahmed Alwbari, Bernardo Rapoport, Ece Esin, Hassan Jaafar, Jamal Zekri, Narjiss Berrada, Ozgur Ozyilkan, Nagi El Saghir
Format:	Article
Language:	English
Published:	Shiraz University of Medical Sciences 2025-10-01
Subjects:	breast neoplasms her2-low immunoconjugates trastuzumab deruxtecan sacituzumab govitecan
Online Access:	https://mejc.sums.ac.ir/article_50590_31ce17421f15ccce87c42b6fa6221037.pdf

Similar Items

Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan
by: Stefano Testa, et al.
Published: (2023-09-01)

Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles
by: Mary Anne Fenton, et al.
Published: (2023-11-01)

Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis
by: George W. Jr. Sledge, et al.
Published: (2025-08-01)

Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study
by: E. Fountzilas, et al.
Published: (2025-03-01)

Comparative pharmacological analysis of fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy: Two recently developed chemotherapies in the crucial battle against breast cancer
by: Amjad Z. Alrosan, et al.
Published: (2025-06-01)

Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer
by: Giuseppe Saltalamacchia, et al.
Published: (2024-02-01)

Interobserver variability in her2 immunohistochemistry analysis and its clinical implications with the advent of the HER2-low category
by: Ana Catharina Joaquim, et al.
Published: (2025-08-01)

Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions
by: Yujun Tong, et al.
Published: (2024-11-01)

Concordance of HER2-low scoring in breast carcinomas among pathologists
by: Snježana Tomić, et al.
Published: (2025-07-01)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
by: Alena Rudkouskaya, et al.
Published: (2020-12-01)

How I treat HER2-low advanced breast cancer
by: Ilana Schlam, et al.
Published: (2023-02-01)

The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers
by: Joseph Edward Haigh, et al.
Published: (2024-09-01)

Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
by: Manikandan Dhanushkodi
Published: (2019-01-01)

Sacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysis
by: Geneva Guarin, et al.
Published: (2024-11-01)

Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes
by: Semir Vranic
Published: (2023-03-01)

A Dramatic Clinical Response to Trastuzumab-Deruxtecan in a Patient with HER-2 Low Breast Cancer with Untreated Leptomeningeal Metastasis and Hydrocephalus
by: Sarah Hussain, et al.
Published: (2025-01-01)

Synthesized Anti-HER2 Trastuzumab-MCC-DM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity
by: Soodabeh Shafiee, et al.
Published: (2023-09-01)

Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literature
by: Axel de Bernardi, et al.
Published: (2024-01-01)

Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma
by: Michael Kim, et al.
Published: (2025-08-01)

Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy
by: Markus Falk, et al.
Published: (2023-01-01)

Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system
by: Xiujuan Gui, et al.
Published: (2023-10-01)

Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy
by: Jinmei Zhou, et al.
Published: (2025-05-01)

HER2-Low Breast Cancer: Current Landscape and Future Prospects
by: Shirman Y, et al.
Published: (2023-08-01)

Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus
by: Emad Dawoud, et al.
Published: (2025-01-01)

Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2− Metastatic Breast Cancer
by: Hope S. Rugo, et al.
Published: (2025-03-01)

HER2 Low Status and Intratumoral Heterogeneity in Epithelial Malignancies and Their Therapeutic Implications
by: Anjali Sharma, et al.

Dramatic Recovery of Vision after Trastuzumab Deruxtecan Treatment of HER2-Positive Breast Cancer with Pituitary Metastasis
by: Chiaki Matsui, et al.
Published: (2023-07-01)

HER2-low breast cancer. Diagnostics, treatment and its adverse events
by: Hanna Bartkowiak, et al.
Published: (2024-12-01)

Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report
by: Chen Y, et al.
Published: (2024-07-01)

A Meta-Analysis to Assess the Efficacy of HER2-Targeted Treatment Regimens in HER2-Positive Metastatic Colorectal Cancer (mCRC)
by: Akshit Chitkara, et al.
Published: (2023-09-01)

An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX for HER2-low gastroesophageal adenocarcinoma
by: Y. Aoki, et al.
Published: (2025-09-01)

Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04
by: Mei Zhan, et al.
Published: (2023-06-01)

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
by: Mythili Shastry, et al.
Published: (2022-12-01)

Long-Term Complete Response to Trastuzumab Deruxtecan in a Case of Unresectable Gastric Cancer
by: Hiroaki Yamane, et al.
Published: (2024-03-01)

Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial
by: Vincenzo Nasca, et al.
Published: (2025-04-01)

Response of Brain and Meningeal Metastases to Trastuzumab-Deruxtecan in a Patient with HER2-Low Breast Cancer: A Case Report
by: Benita Wolf, et al.
Published: (2023-11-01)

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
by: Anna-Maria Lazaratos, et al.
Published: (2023-06-01)

Multicenter prospective EN-MARK study: efficacy of third-line trastuzumab deruxtecan and dynamic changes in biomarkers, including HER2 status
by: A. Ooki, et al.
Published: (2025-12-01)

Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
by: Zongyu Li, et al.
Published: (2023-06-01)

Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)
by: Gavin P. Dowling, et al.
Published: (2024-01-01)